Онлайн КрасотаКаталог

Брошюра «Клинические исследования пептидных биорегуляторов» Электронная версия на английском языке — страница 49

Книги и пособия · 125 страниц · 0.7 МБ · Полное издание

Читать текстСкачать PDF
Svetinorm® RESEARCH RESULTS After treatment with SVETINORM®, most patients noted the disappearance of weakness, an increase in appetite and performance. In 53% of patients, the intensity of pain syndrome significantly decreased. Cancer patients noted an improvement in their well-being, a decrease in weakness, and decreased intensity of dyspeptic disorders Influence of SVETINORM® on the biochemical parameters of peripheral Table 2 blood of patients with chronic hepatitis. Indicator Before After Treatment with After Treatment with Treatment Conventional Means Svetinorm® Cholesterol, (mmol/l) 4,6±0,2 5,2±0,3 5,0±0,4 Bilirubin, (μmol/l) 27,1±1,2 23,6±1,4 20,1±0,8* AST, (mmol /h•l) 41,0±2,5 39,1±2,7 38,8±2,6 ALT, (mmol/h•l) 52,5±4,1 46,1±3,8* 43,5±3,5* ƴ-HT, (mmol / h•l) 44,7±4,3 42,6±4,0 41,4±4,1 Triglycerides, (mmol/l) 2,3±0,1 2,1±0,4 1,7±0,6* * P <0.05 - significant compared with the indicator before treatment. When analyzing the effectiveness of SVETINORM®, particular attention was paid to assessing the results of the biochemical studies characterizing the aminotransferase activity, pigment, and protein- forming functions of the liver. Objectively, after the use of SVETINORM®, the stabilization of the biochemical parameters was observed in most patients: the level of bilirubin, alanine aminotransferase (Table 2). The study of peripheral blood immunoglobulins, an essential criterion for the inflammatory process activity, after a course of treatment with SVETINORM®, showed a decrease in IgM level (Table 3). Influence of SVETINORM® on immunological parameters in patients with Table 3 chronic hepatitis. Indicators Before After Treatment with After Treatment with Svetinorm® Treatment Conventional Means IgA, (g/l) 2,20±0,1 2,30±0,04 2,10±0,06 IgM, (g/l) 3,90±0,05 2,30±0,07* 1,60±0,04* IgG, (g/l) 14,5±1,0 13,7±1,1 14,0±1,2 * P <0.05 - significant compared with the indicators before treatment.

Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.

Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.